Alternative treatment paradigm for thalassemia using iron chelators

Experimental Hematology

Volumn 36, Issue 7, 2008, Pages 773-785

  Szuber, Natasha ^a,b   Buss, Joan L ^c   Soe Lin, Shan ^a,b   Felfly, Hady ^d   Trudel, Marie ^d,e   Ponka, Prem ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; METHEMOGLOBIN; PYRIDOXAL 2 CHLOROBENZOYL HYDRAZONE; PYRIDOXAL ISONICOTINOYL HYDRAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETICULOCYTE; THALASSEMIA;

ANIMALS; BETA-THALASSEMIA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTE MEMBRANE; ERYTHROCYTE TRANSFUSION; HUMANS; IRON; IRON CHELATING AGENTS; METHEMOGLOBIN; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; OXIDATIVE STRESS; RETICULOCYTES;

MUS;

EID: 52449135578     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.01.006     Document Type: Article

References (72)

1. Gaziev J., Sodani P., Polchi P., Andreani M., and Lucarelli G. Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Ann N Y Acad Sci 1054 (2005) 196-205
2. Hebbel R.P. The sickle erythrocyte in double jeopardy: autoxidation and iron decompartmentalization. Semin Hematol 27 (1990) 51-69
3. Weatherall D.J. Pathophysiology of thalassemia. Baillière's Clin Haematol 11 (1998) 127-146
4. Rund D., and Rachmilewitz E.A. Pathophysiology of α- and β-thalassemia: therapeutic implications. Semin Hematol 38 (2001) 343-349
5. Testa U., Hinard N., Beuzard Y., et al. Excess α chains are lost from β-thalassemic reticulocytes by proteolysis. J Lab Clin Med 98 (1981) 352-363
6. Olivieri N.F., and Weatherall D.J. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 10 (1998) 1655-1658
7. Weiss M.J., Zhou S., Feng L., et al. Role of alpha-hemoglobin stabilizing protein in normal erythropoiesis and beta-thalassemia. Ann N Y Acad Sci 1054 (2005) 103-117
8. Wainscoat J.S., Kanavakis E., Wood W.G., et al. Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol 53 (1983) 411-416
9. Rachmilewitz E.A. Denaturation of the normal and abnormal hemoglobin molecule. Semin Hematol 11 (1974) 441-462
10. Repka T., Shalev O., Reddy R., et al. Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes. Blood 82 (1993) 3204-3210
11. Grinberg L.N., Rachmilewitz E.A., Kitrossky N., and Chevion M. Hydroxyl radical generation in beta-thalassemic red blood cells. Free Radic Biol Med 18 (1995) 611-615
12. Schrier S.L. Pathophysiology of thalassemia. Curr Opin Hematol 9 (2002) 123-126
13. Pootrakul P., Kitcharoen K., Yansukon P., et al. The effect of erythroid hyperplasia on iron balance. Blood 71 (1988) 1124-1129
14. Vecchio C., and Derchi G. Management of cardiac complications in patients with thalassemia major. Semin Hematol 32 (1995) 288-296
15. Wonke B. Clinical management of β-thalassemia major. Semin Hematol 38 (2001) 350-359
16. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3452-3455
17. Giardina P.J., and Grady R.W. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 32 (1995) 304-312
18. Modell B., Khan M., and Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355 (2000) 2051-2052
19. Shalev O., Repka T., Goldfarb A., et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 86 (1995) 2008-2013
20. Browne P.V., Shalev O., Kuypers F.A., et al. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J Clin Invest 100 (1997) 1459-1464
21. Olivieri N.F., Brittenham G.M., McLaren C.E., et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339 (1998) 417-422
22. De Franceschi L., Shalev O., Piga A., et al. Deferiprone therapy in homozygous human β-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med 133 (1999) 64-69
23. Rombos Y., Tzanetea R., Konstantopoulos K., et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 85 (2000) 115-117
24. Richardson D.R. The controversial role of deferiprone in the treatment of thalassemia. J Lab Clin Med 137 (2001) 324-329
25. Cohen A.R., Galanello R., Piga A., De Sanctis V., and Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102 (2003) 1583-1587
26. Anderson L.J., Wonke B., Prescott E., Holden S., Walker J.M., and Pennell D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360 9332 (2002) 516-520
27. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107 (2006) 3436-3441
28. Kontoghiorghes G.J. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 6 (2007) 235-239
29. Ponka P., Borova J., Neuwirt J., and Fuchs O. Mobilization of iron from reticulocytes: identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97 (1979) 317-321
30. Baker E., Vitolo M.L., and Webb J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 34 (1985) 3011-3017
31. Ponka P., Richardson D.R., Baker E., Schulman H.M., and Edward J.T. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta 967 (1988) 122-129
32. Baker E., Richardson D.R., Gross S., and Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15 (1992) 492-501
33. Buss J.L., Hermes-Lima M., and Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv Exp Med Biol 509 (2002) 205-229
34. Buss J.L., Arduini E., and Ponka P. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochem Pharmacol 61 (2002) 1689-1701
35. Buss J.L., Arduini E., Shephard K.C., and Ponka P. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. Biochem Pharmacol 65 (2003) 349-360
36. Cikrt M., Ponka P., Necas E., and Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol 45 (1980) 275-283
37. Blaha K., Cikrt M., Nerudova J., Fornuskova H., and Ponka P. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 91 (1998) 4368-4372
38. Scott M.D., Rouyer-Fessard P., Lubin B.H., and Beuzard Y. Entrapment of purified alpha-hemoglobin chains in normal erythrocytes: a model for β-thalassemia. J Biol Chem 265 (1990) 17953-17959
39. Scott M.D., van den Berg J.J., Repka T., et al. Effect of excess α-hemoglobin chains on cellular and membrane oxidation in model β-thalassemic erythrocytes. J Clin Invest 91 (1993) 1706-1712
40. min-globin genes in embryonic stem cells. Proc Natl Acad Sci 92 (1995) 9259-9263
41. Beauchemin H., Blouin M.-J., and Trudel M. Differential regulatory and compensatory responses in hematopoiesis/erythropoiesis in α- and β-globin hemizygous mice. J Biol Chem 279 (2004) 19471-19480
42. Bucci E., and Fronticelli C. A new method for the preparation of α- and β-subunits of human hemoglobin. J Biol Chem 240 (1965) 551-552
43. Turci S.M., and McDonald M.J. Isolation of normal and variant hemoglobin chains. J Chromatogr 343 (1985) 168-174
44. Scott M.D., Eaton J.W., Kuypers F.A., Chiu D.T.-Y., and Lubin B.H. Enhancement of erythrocyte superoxide dismutase activity: effects on cellular oxidant defense. Blood 74 (1989) 2542-2549
45. Scott M.D., Kuypers F.A., Butikofer P., Bookchin R.M., Ortiz O., and Lubin B.H. Effect of osmotic lysis-resealing on red cell structure and function. J Lab Clin Med 115 (1990) 470-480
46. Dodge J.T., Mitchell C., and Hanahan D.J. The preparation and characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys 100 (1963) 119-130
47. Kuross S.A., Rank B.H., and Hebbel R.P. Excess heme in sickle erythrocyte inside-out membranes: possible role in thiol oxidation. Blood 71 (1988) 876-882
48. Edward J.T., Gauthier M., Chubb F.L., and Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data 33 (1988) 538-540
49. Ponka P., Borova J., Neuwirt J., Fuchs O., and Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586 (1979) 278-297
50. 59Fe. Biochim Biophys Acta 757 (1983) 306-315
51. Morgan E.H. Chelator-mediated iron efflux from reticulocytes. Biochim Biophys Acta 733 (1983) 39-50
52. Richardson D.R., Mouralian C., Ponka P., and Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536 (2001) 133-140
53. Beddington R.S., and Robertson E.J. An assessment of the developmental potential of embryonic stem cells in the midgestation mouse embryo. Development 105 (1989) 733-737
54. Alzet Mini-Osmotic Pump Model 2001 Instruction and Specification Sheet, Alzet Technical Information Services. Cupertino, CA: DURECT Corporation.
55. Beutler E.A., Hoffbrand V., and Cook J.D. Iron deficiency and overload. The American Society of Hematology Education Program Book (2003), American Society of Hematology, Washington, DC 40-61
56. Brittenham G.M. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol 27 (1990) 112-116
57. Tricta F., and Spino M. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 339 (1998) 1710
58. Hershko C., Avramovici-Grisaru S., Link G., Gelfland L., and Sarel S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med 98 (1981) 99-108
59. Johnson D.K., Pippard M.J., Murphy T.B., and Rose N.J. An in vivo evaluation of iron chelating drugs derived from pyridoxal and its analogs. J Pharmacol Exp Ther 221 (1982) 399-403
60. Sterba M., Simunek T., Mazurova Y., et al. Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Hum Exp Toxicol 24 (2005) 581-589
61. Sterba M., Popelova O., Simunek T., et al. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther 319 (2006) 1336-1347
62. Kuross S.A., and Hebbel R.P. Nonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation. Blood 72 (1988) 1278-1285
63. Szebeni J., Winterbourn C.C., and Carrell R.W. Oxidative interactions between haemoglobin and membrane lipid: a liposome model. Biochem J 220 (1984) 685-692
64. Winterbourn C.C. Reactions of superoxide with hemoglobin. In: Greenwald R.A. (Ed). CRC Handbook of Methods for Oxygen Radical Research (1986), CRC Press, Boca Raton, FL 137-141
65. Hoffmann-Fezer G., Maschke H., Zeitler H.J., et al. Direct in vivo biotinylation of erythrocytes as an assay for red cell survival studies. Ann Hematol 63 (1991) 214-217
66. Pountney D.J., Konijn A.M., McKie A.T., Peters T.J., and Raja K.B. Iron proteins of duodenal enterocytes isolated from mice with genetically and experimentally altered iron metabolism. Br J Haematol 105 (1999) 1066-1073
67. Ferreira C., Santambrogio P., Martin M.-E., et al. H ferritin knockout mice: a model of hyperferritinemia in the absence of iron overload. Blood 98 (2001) 525-532
68. Ansell J., and Micklem H. Genetic markers for following cell populations. In: Weir D.M., Herzenberg L.A., and Blackwell C.C. (Eds). Handbook of Experimental Immunology. 4th ed. (1986), Blackwell Publishers, Edinburgh, Scotland 56 1-56.18
69. Ploemacher R.E., van Os R., van Beurden C.A., and Down J.D. Murine hematopoietic stem cells with long-term engraftment and marrow repopulating ability are less radiosensitive to gamma radiation than are spleen colony forming cells. Int J Radiat Biol 61 (1992) 489-499
70. de Franceschi L., Turrini F., Honczarenko M., et al. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica 89 (2004) 1287-1298
71. Link G., Ponka P., Konijn A.M., Breuer W., Cabantchik Z.I., and Hershko C. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 101 (2003) 4172-4179
72. Ponka P., Grady R.W., Wilczynska A., and Schulman H.M. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim Biophys Acta 802 (1984) 477-489